Thyroid Gland Carcinoma Clinical Trials

6 recruiting

Thyroid Gland Carcinoma Trials at a Glance

15 actively recruiting trials for thyroid gland carcinoma are listed on ClinicalTrialsFinder across 6 cities in 3 countries. The largest study group is Phase 2 with 3 trials, with the heaviest enrollment activity in Houston, Los Angeles, and Chicago. Lead sponsors running thyroid gland carcinoma studies include M.D. Anderson Cancer Center, Jonsson Comprehensive Cancer Center, and Mayo Clinic.

Browse thyroid gland carcinoma trials by phase

Treatments under study

About Thyroid Gland Carcinoma Clinical Trials

Looking for clinical trials for Thyroid Gland Carcinoma? There are currently 6 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Thyroid Gland Carcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Thyroid Gland Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 115 of 15 trials

Recruiting
Not Applicable

Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial

Metastatic Malignant Solid NeoplasmMetastatic MelanomaMetastatic Renal Cell Carcinoma+15 more
M.D. Anderson Cancer Center40 enrolled1 locationNCT04693377
Recruiting

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Head and Neck CarcinomaMalignant Solid NeoplasmSarcoma+59 more
Alliance for Clinical Trials in Oncology2,000 enrolled745 locationsNCT05334069
Recruiting

Identification and Differentiation of Thyroid Nodules by Acoustic Imaging and Viscoelastic Parameters

Thyroid Gland Carcinoma
Mayo Clinic650 enrolled3 locationsNCT06207188
Recruiting
Phase 3

Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer

Refractory Differentiated Thyroid Gland Carcinoma
ECOG-ACRIN Cancer Research Group264 enrolled112 locationsNCT06475989
Recruiting

Development of Liquid Biopsy Technologies for Noninvasive Cancer Diagnostics in Patients With Suspicious Thyroid Nodules or Thyroid Cancer

Thyroid Gland CarcinomaThyroid Gland Nodule
Jonsson Comprehensive Cancer Center250 enrolled1 locationNCT04742608
Recruiting

Evaluation of 18F-TFB PET/CT Scan in Patients With Differentiated Thyroid Cancer

Thyroid Gland Follicular CarcinomaThyroid Gland Papillary CarcinomaDifferentiated Thyroid Gland Carcinoma
Mayo Clinic24 enrolled1 locationNCT05575440
Recruiting
Not Applicable

Evaluation of DNA Methylation Signatures for the Diagnosis and Management of Thyroid Nodules

Thyroid Gland Carcinoma
City of Hope Medical Center1,450 enrolled1 locationNCT05229341
Recruiting
Phase 1

An Investigational Scan (hpMRI) for Monitoring Treatment Response in Patients With Thyroid Cancer and Other Malignancies of the Head and Neck Undergoing Radiation Therapy and/or Systemic Therapy

Thyroid Gland Carcinoma
M.D. Anderson Cancer Center42 enrolled1 locationNCT04589624
Recruiting

Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors

Malignant Brain NeoplasmMalignant Solid NeoplasmMalignant Testicular Neoplasm+97 more
University of Southern California250 enrolled1 locationNCT07259304
Recruiting

Molecular and Immunohistochemical Profiling of Tumors in Patients With Parathyroid Tumors

Primary HyperparathyroidismParathyroid Gland CarcinomaParathyroid Gland Atypical Adenoma+1 more
M.D. Anderson Cancer Center310 enrolled1 locationNCT03039439
Recruiting
Phase 1

Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers

Breast CarcinomaUrothelial CarcinomaOvarian Carcinoma+31 more
Jonsson Comprehensive Cancer Center30 enrolled1 locationNCT07118176
Recruiting
Phase 2

XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer

Stage III Differentiated Thyroid Gland Carcinoma AJCC v8Refractory Differentiated Thyroid Gland CarcinomaLocally Advanced Differentiated Thyroid Gland Carcinoma+18 more
Northwestern University33 enrolled1 locationNCT06959641
Recruiting

Institution of an Italian Multicenter Database of Patients with Parathyroid Carcinoma or Atypical Parathyroid Adenoma

Parathyroid Gland CarcinomaParathyroid Gland Atypical Adenoma
F.I.R.M.O. - Fondazione Italiana Ricerca sulle Malattie dell'Osso - Ente del Terzo Settore300 enrolled33 locationsNCT06645951
Recruiting
Phase 2

Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC

Thyroid CancerThyroid CarcinomaPapillary Thyroid Cancer+3 more
Massachusetts General Hospital30 enrolled6 locationsNCT05668962
Recruiting
Phase 2

Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer

Locally Advanced Thyroid Gland Carcinoma
West China Hospital75 enrolled1 locationNCT06482086